ACR24 JAK_TYK Topic Panel

David Liew, a renowned rheumatologist from Melbourne, joins an expert panel to discuss groundbreaking findings from the ACR Annual Meeting. They explore the effectiveness of Upadacitinib for treating giant cell arteritis and the complexities surrounding patient enrollment for trials. The conversation shifts to the skepticism around methotrexate for polymyalgia rheumatica and the potential of JAK inhibitors in myositis. Safety concerns regarding these therapies, particularly in cardiovascular health, underscore the importance of ongoing research.